Merck & Co. Inc. (NYSE: MRK) is 14.18% higher on its value in year-to-date trading and has touched a low of $71.50 and a high of $95.72 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The MRK stock was last observed hovering at around $84.53 in the last trading session, with the day’s gains setting it 2.98% off its average median price target of $100.00 for the next 12 months. It is also 29.99% off the consensus price target high of $125.00 offered by 25 analysts, but current levels are -2.95% lower than the price target low of $85.00 for the same period.
Currently trading at $87.51, the stock is 0.37% and -1.80% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 12.33 million and changing 3.53% at the moment leaves the stock 3.45% off its SMA200. MRK registered 21.47% gain for a year compared to 6-month gain of 9.76%.
The stock witnessed a -2.98% loss in the last 1 month and extending the period to 3 months gives it a -4.88%, and is 0.88% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.16% over the week and 1.77% over the month.
Merck & Co. Inc. (MRK) has around 68000 employees, a market worth around $219.24B and $57.17B in sales. Current P/E ratio is 13.34 and Fwd P/E is 11.75. Profit margin for the company is 29.00%. Distance from 52-week low is 22.39% and -8.58% from its 52-week high. The company has generated returns on investments over the last 12 months (15.50%).
Merck & Co. Inc. (MRK) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Merck & Co. Inc. (MRK) is a “Overweight”. 25 analysts offering their recommendations for the stock have an average rating of 2.20, where 10 rate it as a Hold and 3 think it is a “Overweight”. 12 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Merck & Co. Inc. is expected to release its quarterly report on 10/27/2022.The EPS is expected to grow by 173.50% this year
Merck & Co. Inc. (MRK) Top Institutional Holders
The shares outstanding are 2.53B, and float is at 2.53B with Short Float at 0.76%.
Merck & Co. Inc. (MRK) Insider Activity
A total of 42 insider transactions have happened at Merck & Co. Inc. (MRK) in the last six months, with sales accounting for 21 and purchases happening 21 times. The most recent transaction is an insider sale by FRAZIER KENNETH C, the company’s Executive Chair. SEC filings show that FRAZIER KENNETH C sold 663,881 shares of the company’s common stock on Nov 09 at a price of $82.26 per share for a total of $54.61 million. Following the sale, the insider now owns 0.59 million shares.
Merck & Co. Inc. disclosed in a document filed with the SEC on Nov 04 that DeLuca Richard R. (EVP&Pres, Merck Animal Heallth) sold a total of 29,782 shares of the company’s common stock. The trade occurred on Nov 04 and was made at $90.40 per share for $2.69 million. Following the transaction, the insider now directly holds 0.12 million shares of the MRK stock.
Still, SEC filings show that on Nov 04, Litchfield Caroline (EVP & CFO) disposed off 18,335 shares at an average price of $91.00 for $1.67 million. The insider now directly holds 24,114 shares of Merck & Co. Inc. (MRK).
Merck & Co. Inc. (MRK): Who are the competitors?
The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading 1.37% up over the past 12 months and Pfizer Inc. (PFE) that is 1.41% higher over the same period.